{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105022","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.081472+00:00","generated_at":"2026-05-17T18:06:54.170341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial","bullets":["Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.","Cash, equivalents and investments $656.8M, expected to fund operations into 2029.","RLY-2608 + fulvestrant Phase 1b data: 10.3-month median PFS, 39% ORR in PI3Kα-mutated HR+/HER2- mBC.","Initiated Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant vs capivasertib + fulvestrant.","R&D expenses decreased to $63.9M from $92.0M due to streamlining and license agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105022","json":"https://secwatch.observer/filing/0000950170-25-105022.json","markdown":"https://secwatch.observer/filing/0000950170-25-105022.md","text":"https://secwatch.observer/filing/0000950170-25-105022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/0000950170-25-105022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/rlay-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:06:54.170341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}